230 related articles for article (PubMed ID: 32292093)
1. Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?
Bergonzini C; Leonetti A; Tiseo M; Giovannetti E; Peters GJ
Expert Opin Pharmacother; 2020 Aug; 21(11):1287-1298. PubMed ID: 32292093
[TBL] [Abstract][Full Text] [Related]
2. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
3. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.
Nagano T; Tachihara M; Nishimura Y
Drugs Today (Barc); 2019 Apr; 55(4):231-236. PubMed ID: 31050691
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
Lavacchi D; Mazzoni F; Giaccone G
Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
[TBL] [Abstract][Full Text] [Related]
6. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Lee M; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Wu YL
J Clin Oncol; 2018 Aug; 36(22):2244-2250. PubMed ID: 29864379
[TBL] [Abstract][Full Text] [Related]
7. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
Walia M; Singhal MK; Kamle MS
Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
[TBL] [Abstract][Full Text] [Related]
8. Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer.
Santarpia M; Menis J; Chaib I; Gonzalez Cao M; Rosell R
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):831-840. PubMed ID: 31356117
[No Abstract] [Full Text] [Related]
9. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
10. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
Ramalingam SS; O'Byrne K; Boyer M; Mok T; Jänne PA; Zhang H; Liang J; Taylor I; Sbar EI; Paz-Ares L
Ann Oncol; 2016 Mar; 27(3):423-9. PubMed ID: 26768165
[TBL] [Abstract][Full Text] [Related]
11. A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations.
Li HS; Zhang JY; Yan X; Xu HY; Hao XZ; Xing PY; Wang Y
Cancer Med; 2022 Feb; 11(4):1026-1036. PubMed ID: 35023313
[TBL] [Abstract][Full Text] [Related]
12. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.
Lau SCM; Batra U; Mok TSK; Loong HH
Drugs; 2019 Jun; 79(8):823-831. PubMed ID: 31069718
[TBL] [Abstract][Full Text] [Related]
13. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
Lu S; Shih JY; Jang TW; Liam CK; Yu Y
Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
[TBL] [Abstract][Full Text] [Related]
14. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Liao BC; Lin CC; Yang JC
Curr Opin Oncol; 2015 Mar; 27(2):94-101. PubMed ID: 25611025
[TBL] [Abstract][Full Text] [Related]
15. Dacomitinib, a new therapy for the treatment of non-small cell lung cancer.
Brzezniak C; Carter CA; Giaccone G
Expert Opin Pharmacother; 2013 Feb; 14(2):247-53. PubMed ID: 23294134
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).
Zhang B; Shi C; Gao Z; Zhong H; Xiong L; Gu A; Wang W; Chu T; Zhang W; Wang H; Zhang X; Zhong R; Han B
BMC Cancer; 2022 Mar; 22(1):294. PubMed ID: 35305596
[TBL] [Abstract][Full Text] [Related]
17. Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.
Peng W; Pu X; Jiang M; Wang J; Li J; Li K; Xu Y; Xu F; Chen B; Wang Q; Cao J; Chen Y; Wu L
Lung Cancer; 2021 Feb; 152():66-70. PubMed ID: 33352385
[TBL] [Abstract][Full Text] [Related]
18. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (
Nilsson FOL; Gal P; Houisse I; Ivanova JI; Asanin ST
J Med Econ; 2021; 24(1):447-457. PubMed ID: 33754924
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases.
Zhang J; Wang Y; Liu Z; Wang L; Yao Y; Liu Y; Hao XZ; Wang J; Xing P; Li J
Thorac Cancer; 2021 Dec; 12(24):3407-3415. PubMed ID: 34751504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]